Abstract
Novel therapies targeting herpes simplex virus type 1 (HSV-1) are needed, as acyclovir resistant strains can emerge and cause severe complications. In this paper, we show the antiviral efficacy of a novel antiviral RNA treatment upon intranasal administration to mice infected intranasally with HSV-1.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
